Company intelligence / Profile preview

Hanlim Pharm

Seoul, Seoul, South Koreahanlim.com ↗

Ownership: Private
Employees: ~500
Development stage: Other

Overview

Hanlim Pharm has a diverse pipeline, including IMDs, NCEs, and biologics. Notably, HL401 for systemic lupus erythematosus is in preclinical or early clinical development; HL301 (acute bronchitis), HL217 (AMD), and HL237 (rheumatoid arthritis) are at various phases of development. The company emphasizes ethical drugs, ophthalmic products, and combination therapies[3][5].

Therapeutic areas: ImmunologyEndocrinologyOphthalmologyGastroenterologyPulmonology
Modalities: Small moleculeBiologicMesenchymal stem cell therapy
Industry: Biotech

Drug pipeline

16 assets

Livasupril

15 more assets in the full pipeline.

Partnerships

CORESTEM (joint research in lupus treatment)[9]Sanofi (historic sales alliance)[9]Ethypharm (historic technical alliance)[9]GADOR (historic technical alliance)[9]GRAAF (historic technical alliance)[9]

Beyond the preview

Go deeper on Hanlim Pharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hanlim Pharm.